Literature DB >> 20021324

Temporal characteristics of botulinum neurotoxin therapy.

Frank J Lebeda1, Regina Z Cer, Robert M Stephens, Uma Mudunuri.   

Abstract

Botulinum neurotoxin is a pharmaceutical treatment used for an increasing number of neurological and non-neurological indications, symptoms and diseases. Despite the wealth of clinical reports that involve the timing of the therapeutic effects of this toxin, few studies have attempted to integrate these data into unified models. Secondary reactions have also been examined including the development of adverse events, resistance to repeated applications, and nerve terminal sprouting. Our primary intent for conducting this review was to gather relevant pharmacodynamic data from suitable biomedical literature regarding botulinum neurotoxins via the use of automated data-mining techniques. We envision that mathematical models will ultimately be of value to those who are healthcare decision makers and providers, as well as clinical and basic researchers. Furthermore, we hypothesize that the combination of this computer-intensive approach with mathematical modeling will predict the percentage of patients who will favorably or adversely respond to this treatment and thus will eventually assist in developing the increasingly important area of personalized medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20021324      PMCID: PMC2842014          DOI: 10.1586/ern.09.134

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  70 in total

1.  Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles.

Authors:  Neil S Sadick
Journal:  Dermatol Surg       Date:  2003-05       Impact factor: 3.398

2.  Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation.

Authors:  Frédéric A Meunier; Godfrey Lisk; Dorothea Sesardic; J Oliver Dolly
Journal:  Mol Cell Neurosci       Date:  2003-04       Impact factor: 4.314

Review 3.  Identification of the major steps in botulinum toxin action.

Authors:  Lance L Simpson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

4.  Botulinum A exotoxin for the management of platysma bands.

Authors:  Alan Matarasso; Seth L Matarasso
Journal:  Plast Reconstr Surg       Date:  2003-10       Impact factor: 4.730

5.  Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides.

Authors:  Seth L Matarasso
Journal:  Dermatol Surg       Date:  2003-01       Impact factor: 3.398

6.  Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy.

Authors:  Dirk Dressler
Journal:  Eur Neurol       Date:  2002       Impact factor: 1.710

7.  Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study.

Authors:  Neil S Sadick
Journal:  Dermatol Surg       Date:  2002-09       Impact factor: 3.398

8.  Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.

Authors:  Nicholas J Lowe; Paul S Yamauchi; Gary P Lask; Rickie Patnaik; Donna Moore
Journal:  J Cosmet Laser Ther       Date:  2002-03       Impact factor: 2.247

9.  Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.

Authors:  K Roger Aoki
Journal:  Toxicon       Date:  2002-07       Impact factor: 3.033

10.  BotDB: A database resource for the clostridial neurotoxins.

Authors:  Frank J Lebeda
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

View more
  5 in total

1.  Systems analysis of transcriptional data provides insights into muscle's biological response to botulinum toxin.

Authors:  Kavitha Mukund; Margie Mathewson; Viviane Minamoto; Samuel R Ward; Shankar Subramaniam; Richard L Lieber
Journal:  Muscle Nerve       Date:  2014-03-17       Impact factor: 3.217

Review 2.  The zinc-dependent protease activity of the botulinum neurotoxins.

Authors:  Frank J Lebeda; Regina Z Cer; Uma Mudunuri; Robert Stephens; Bal Ram Singh; Michael Adler
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

3.  Kinetic and reaction pathway analysis in the application of botulinum toxin a for wound healing.

Authors:  Frank J Lebeda; Zygmunt F Dembek; Michael Adler
Journal:  J Toxicol       Date:  2011-11-24

4.  IGF-1 antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength.

Authors:  Lingjing Jin; Lizhen Pan; Wuchao Liu; Yan Guo; Yuguo Zheng; Qiang Guan; Zhiyu Nie
Journal:  Int J Mol Sci       Date:  2013-04-25       Impact factor: 5.923

5.  Botulinum Toxin-Chitosan Nanoparticles Prevent Arrhythmia in Experimental Rat Models.

Authors:  David Sergeevichev; Vladislav Fomenko; Artem Strelnikov; Anna Dokuchaeva; Maria Vasilieva; Elena Chepeleva; Yanina Rusakova; Sergey Artemenko; Alexander Romanov; Nariman Salakhutdinov; Alexander Chernyavskiy
Journal:  Mar Drugs       Date:  2020-08-02       Impact factor: 5.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.